Celladon - Barchart's Chart of the Day

Celladon (CLDN) is Barchart's Chart of the Day.  The biomedical company has a Trend Spotter buy signal, a Weighted Alpha of 55.20+ and gained 132.03% in the last year.

The Chart of the Day belongs to Celladon (CLDN).  I found the stock by sorting the All Time High list for the stocks hitting the most frequent highs in the last month, then used the Flipchart feature to review the charts.  Since the Trend Spotter signaled a buy on 10/27 the stock gained 81.38%.

Celladon Corporation is a biotechnology company. It focuses on developing treatments for heart failure, diabete and neurodegenerative diseases. The company's lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca2+-ATPase 2a enzyme deficiency in heart failure patients. Its MYDICAR product is developed to treat patients with systolic heart failure, diastolic heart failure and advanced heart failure as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure.

 Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

• 100% Barchart technical buy signals
• Trend Spotter buy signal
• Above its 20, 50 and 100 day moving averages
• 13 new highs and up 63.06% in the last month
• Relative Strength Index 78.66%
• Barchart computes a technical support level at 15.46
• Recently traded at 18.94 with a 50 day moving average of 12.10

Fundamental factors:

• Not widely followed so projections are slim
• Market Cap $426.72 million
• Revenue expected to grow 93.60% this year and another 22.00% next year
• Wall Street analysts issued 2 strong buy recommendations on the stock
• The individual investors on Motley Fool voted 13 to 2 that the stock will beat the market

This stock has had a very steep run up recently if you have it be prepared to skim off some profits.  If you're not in it yet, I think you missed the boat.